Cambridge Antibody, Drug Royalty, Inwest Investments Ltd. deal

Holding company Inwest acquired DRI for C$3.05 in cash for each DRI share, valuing the deal at C$133 million (US$83.5 million). CAT originally proposed to acquire DRI in a stock deal valuing DRI at C$3.10 per share, but in March, DRI's board withdrew its recommendation of accepting CAT's bid and instead recommended accepting the Inwest offer. ...